person · Reporting owner
Van Strydonck, Gerald E.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 543 |
Reported balance
After 2024-05-10 transaction · row 1
1 source rowRow 1 · 2024-05-10 · Grant · Acquired 543 · Balance 543 F1: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 | Direct | 10,108 |
Reported balance
After 2024-05-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-05-10 · Grant · Acquired 10,108 · Balance 10,108 F8: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $204.00 · Expires 2027-09-15 | Direct | 426 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 426 F2: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.90 · Expires 2029-03-30 | Direct | 166 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 166 F2: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.70 | Direct | 514 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 514 F3: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $82.80 · Expires 2029-06-29 | Direct | 159 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 159 F2: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2029-09-27 | Direct | 123 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 123 F2: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.75 · Expires 2029-12-28 | Direct | 182 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 182 F2: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.25 | Direct | 1,045 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,045 F4: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.25 | Direct | 1,905 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 1,905 F5: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.80 | Direct | 3,550 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,550 F6: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 | Direct | 9,589 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 9,589 F7: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024.
F2: Exercisable in full as of the date of this report.
F3: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F4: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F5: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F6: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F7: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
F8: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2024 Filed May 14, 2024 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,108 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001062993-24-010183 · form4.xml · derivative · entry 12 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 10,108 shares Expires not disclosed F8 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 543 | $5.75 | $3,122.25 |
DisclosureSEC source: 0001062993-24-010183 · form4.xml · nonDerivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543 F1 · shares: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | SaleCommon Stock | 3,149 | $0.72 | $2,267.28 |
DisclosureSEC source: 0001062993-23-023239 · form4.xml · nonDerivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | SaleCommon Stock | 1,334 | $0.67 | $893.78 |
DisclosureSEC source: 0001062993-23-022436 · form4.xml · nonDerivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,149 Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 143,848 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001062993-23-011108 · form4.xml · derivative · entry 11 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,848 Underlying: Common Stock · 143,848 shares Expires not disclosed F6 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 47,232 | $0.53 | $24,999.90 |
DisclosureSEC source: 0001062993-22-022813 · form4.xml · nonDerivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,232 Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:43 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 53,254 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001062993-22-012388 · form4.xml · derivative · entry 11 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,254 Underlying: Common Stock · 53,254 shares Expires not disclosed F5 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 16:37 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 18,000 | $1.32 | $23,760.00 |
DisclosureSEC source: 0001062993-22-005567 · form4.xml · nonDerivative · entry 2 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 16:37 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 2,000 | $1.30 | $2,600.00 |
DisclosureSEC source: 0001062993-22-005567 · form4.xml · nonDerivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,586 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000891839-21-000136 · edgar.xml · derivative · entry 9 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F4 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:20 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 15,679 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000891839-20-000119 · edgar.xml · derivative · entry 8 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,679 Underlying: Common Stock · 15,679 shares Expires not disclosed F3 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| December 31, 2019 Filed Jan 6, 2020 16:34 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,737 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000891839-20-000018 · edgar.xml · derivative · entry 7 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,737 Underlying: Common Stock · 2,737 shares Expires 2029-12-28 F3 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Oct 4, 2019 10:57 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-052506 · doc4.xml · derivative · entry 6 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F3 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Jan 6, 2020 16:32 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0000891839-20-000016 · edgar.xml · derivative · entry 1 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2029-09-27 F2 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. F1 · derivative.expiration_date: The original Form 4 contained an incorrect expiration date for these options. This amendment is being filed to correct the expiration date. Read SEC document |
| June 30, 2019 Filed Jan 15, 2020 16:20 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,385 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0000891839-20-000030 · edgar.xml · derivative · entry 6 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385 Underlying: Common Stock · 2,385 shares Expires 2029-06-29 F3 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:41 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000070 · edgar.xml · derivative · entry 5 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,501 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0000891839-19-000058 · edgar.xml · derivative · entry 4 Van Strydonck, Gerald E. · CIK 0001748247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 Underlying: Common Stock · 2,501 shares Expires 2029-03-30 F2 · shares: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. F2 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. F2 · derivative.exercise_date: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of the $8,750 cash compensation earned in the first quarter of 2019 for service as a member of the Issuer's board of directors. The number of options was calculated in accordance wih the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.